Yahoo Finance2d
Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...
Drug Store News11d
Celltrion launches Stelara biosimilar
Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar to Johnson & Johnson's Stelara (ustekinumab). Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic ...
Hosted on MSN14d
Celltrion to cancel $140M in treasury shares
Celltrion will cancel treasury shares worth 203.3 billion won ($140 million) to enhance shareholder value, the Korean drugmaker said on Friday. The shares set for cancellation are its entire ...
Morningstar19d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...
Montreal News17d
Celltrion’s Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name RemdantryTM starting April 1, 2025 ...
manilatimes19d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
JERSEY CITY, N.J., March 10, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...